Literature DB >> 1161394

Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines.

R E Weibel, E B Buynak, A A McLean, M R Hilleman.   

Abstract

Antibody in human subjects persisted without substantial decline for 8 years after mumps vaccine (Jeryl Lynn), for 6 years after measles (Attenuvax), for 5 1/2 years after rubella vaccine (HPV-77 duck), for 5 years after measles-mumps-rubella and mumps-rubella combined vaccines, for 4 years after measles and rubella, and for 2 years after measles-mumps vaccines, the longest periods tested. Protective immunity against mumps illness persisted through the eighth year. The patterns for antibody following vaccination parallel those for natural infection and indicate that immunity will be lasting. Subclinical reinfection evidenced by antibody increase was commonly seen in persons who had been vaccinated, much as follows the natural infection.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1161394

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  16 in total

Review 1.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

Review 2.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Virology       Date:  2011-01-08       Impact factor: 3.616

3.  Controversies in viral immunization.

Authors:  M A Chernesky
Journal:  Can Fam Physician       Date:  1979-03       Impact factor: 3.275

4.  Coxsackie B4 viral infection, anti-islet immunity and immunogenetics in insulin-dependent diabetes mellitus.

Authors:  G Schernthaner; H Ludwig; W R Mayr
Journal:  Acta Diabetol Lat       Date:  1978 May-Aug

Review 5.  Measles virus and its associated diseases.

Authors:  E M Morgan; F Rapp
Journal:  Bacteriol Rev       Date:  1977-09

6.  Epidemic of mumps in a partially immune population.

Authors:  J E Lewis; M A Chernesky; M L Rawls; W E Rawls
Journal:  Can Med Assoc J       Date:  1979-09-22       Impact factor: 8.262

Review 7.  Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic Diversity.

Authors:  Eugene Lam; Jennifer B Rosen; Jane R Zucker
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

8.  Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays.

Authors:  Jeremy Mauldin; Kathryn Carbone; Henry Hsu; Robert Yolken; Steven Rubin
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

Review 9.  Complex immune correlates of protection in HIV-1 vaccine efficacy trials.

Authors:  Georgia D Tomaras; Stanley A Plotkin
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

10.  Duration of the immune response to MMR vaccine in children of two age-different groups.

Authors:  S Li Volti; G Giammanco-Bilancia; M Grassi; R Garozzo; R Gluck; G Giammanco
Journal:  Eur J Epidemiol       Date:  1993-05       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.